PRESS RELEASE published on 07/08/2024 at 23:15, 2 years 1 month ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 2 years 1 month ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 2 years 1 month ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
PRESS RELEASE published on 06/20/2024 at 13:00, 2 years 1 month ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 2 years 1 month ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
BRIEF published on 06/19/2024 at 13:05, 2 years 1 month ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
PRESS RELEASE published on 06/19/2024 at 13:00, 2 years 1 month ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 2 years 1 month ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
BRIEF published on 06/18/2024 at 13:05, 2 years 1 month ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
PRESS RELEASE published on 06/18/2024 at 13:00, 2 years 1 month ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 08/14/2026 at 16:55, 1 hour 20 minutes ago SLAM Reports 1.19% Copper Equivalent Over 24.6 Metres in Hole GW26-29 From the Goodwin Copper-Nickel-Cobalt Project
Published on 08/14/2026 at 13:30, 4 hours 45 minutes ago Digi Power X Reports Second Quarter 2026 Financial Results and Provides Operational Update and 2027 Outlook
Published on 08/14/2026 at 13:15, 5 hours ago Mako Mining Reports Q2 2026 Financial Results, Including Adjusted EBITDA(1) of US$31.7 Million and EPS of US$0.16/Share
Published on 08/14/2026 at 13:10, 5 hours 5 minutes ago SouthGobi Announces Second Quarter 2026 Unaudited Financial and Operating Results
Published on 08/14/2026 at 09:01, 9 hours 14 minutes ago Apex Announces Filing of Final Base Shelf Prospectus
Published on 08/14/2026 at 16:05, 2 hours 10 minutes ago GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/14/2026 at 15:02, 3 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/14/2026 at 15:02, 3 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 08/14/2026 at 15:01, 3 hours 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 08/11/2026 at 17:45, 3 days ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
